BRCA1 and ovarian cancer: The phase III SOLO2/ENGOT-Ov21 study showed a numerically but statistically insignificant improvement in the overall goal of survival with olaparib maintenance therapy compared to the placebo in patients with recurrent platinum-sensitive ovarian cancer and a BRCA1/2 mutation (51.7 months vs. 38.8 months) [50].